Loperamide hydrochloride capsule is indicated for the control and symptomatic relief of acute nonspecific diarrhea and chronic diarrhea associated with inflammatory bowel disease. The said drug is equivalent to reference listed drug (RLD), Imodium Capsules.
The pharma company said that the drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.
According to IQVIA MAT, January 2023 data, Loperamide Hydrochloride Capsules USP had annual sales of $34.7 million in the United States.
As of 31 December 2022, the group now has 356 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company's consolidated net profit jumped 24.5% to Rs 622.90 crore on 17.9% rise in net sales to Rs 4,159.80 crore in Q3 FY23 over Q3 FY22.
Shares of Zydus Lifesciences rose 0.52% to Rs 486.90 on the BSE.
Powered by Capital Market - Live News